Aclaris Therapeutics
ACRS
133 hedge funds and large institutions have $737M invested in Aclaris Therapeutics in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 53 increasing their positions, 40 reducing their positions, and 27 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
27% more capital invested
Capital invested by funds: $579M → $737M (+$158M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6.72% less ownership
Funds ownership: 107.32% → 100.6% (-6.7%)
10% less funds holding
Funds holding: 148 → 133 (-15)
21% less call options, than puts
Call options by funds: $13M | Put options by funds: $16.5M
56% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 27
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$8.67M |
| 2 |
Millennium Management
New York
|
+$6.93M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.79M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.75M |
| 5 |
BlackRock
New York
|
+$4.33M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$13.8M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$5.55M |
| 3 |
CC
Commodore Capital
New York
|
-$5.14M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$4.67M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Handelsbanken Fonder
Stockholm,
Sweden
| – | -$120K | -14,800 | Closed |
|
|
PA
152
Profund Advisors
Bethesda,
Maryland
| – | -$112K | -13,869 | Closed |
|
153
Voloridge Investment Management
Jupiter,
Florida
| – | -$91.8K | -11,349 | Closed |
|
|
HCA
154
Hyperion Capital Advisors
New York
| – | -$87.9K | -10,861 | Closed |
|
|
CC
155
Corton Capital
Carrying Place,
Ontario, Canada
| – | -$84.3K | -10,419 | Closed |
|
|
QT
156
Quantbot Technologies
New York
| – | -$70.4K | -8,700 | Closed |
|
157
Amundi
Paris,
France
| – | -$34.4K | -3,975 | Closed |
|
|
TWA
158
TCI Wealth Advisors
Tucson,
Arizona
| – | -$4.27K | -528 | Closed |
|
|
MPWT
159
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$574 | -71 | Closed |
|
ACRS Hedge Fund Activity: Q2 2023 in Review
133 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2023, worth a combined $737M — up 27% from $579M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ACRS and 12 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 53 added.
The largest buyer was Morgan Stanley, adding an estimated $8.67M. The largest seller was Deep Track Capital, exiting entirely with an estimated $13.8M sold.
- 133 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2023, down from 148 in Q1 2023.
- Funds reported $737M of Aclaris Therapeutics stock for Q2 2023, up 27% quarter-over-quarter.
- 12 funds opened new Aclaris Therapeutics positions in Q2 2023 and 27 closed out, a net change of -15 holders.
- The largest Aclaris Therapeutics buyer in Q2 2023 was Morgan Stanley, an estimated $8.67M added.
- The largest Aclaris Therapeutics seller in Q2 2023 was Deep Track Capital, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2023.